证券代码：603707 证券简称：健友股份 公告编号：2025-041 南京健友生化制药股份有限公司 关于以集中竞价方式回购股份的回购报告书 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： ● 回购股份金额：本次回购股份的资金总额不低于人民币 2,000 万元（含）且不 超过人民币 4,000 万元（含） ● 回购股份资金来源：公司自有资金或招商银行股份有限公司南京分行提供的专 项贷款 ● 回购股份期限：自公司股东大会审议通过本次回购股份方案之日起 12 个月内 ● 相关股东是否存在减持计划：截至董事会通过本次回购方案决议日，公司控股 股东、董事、监事、高级管理人员、回购提议人、持股 5%以上股东暂无未来 3 个 月、6 个月的明确减持计划，若未来 3 个月、6 个月内拟实施股份减持计划，公司 及相关方将按照相关规定及时履行信息披露义务。 ● 相关风险提示： （一）回购期限内，若公司股票价格持续超出回购方案披露的价格上限，存在回 购方案无法实施的风险； （二）如对公司股票交易价格产生重大影响的重大事项发生或 ...

Investment Rating - The report maintains a "Buy" rating for the company, indicating an expected relative price increase of over 20% compared to the market benchmark within the next six months [7][18]. Core Views - The company's performance in 2024 met expectations, with a revenue of 3.924 billion yuan, a slight decrease of 0.20% year-on-year, and a net profit of 826 million yuan, a significant increase of 536.09% year-on-year [2][4]. - In Q1 2025, the company experienced a revenue decline of 11.85% year-on-year, totaling 885 million yuan, and a net profit decrease of 52.19%, amounting to 85 million yuan [2][4]. - The report emphasizes that short-term fluctuations do not alter the company's long-term growth potential, particularly as it positions itself as a unique overseas formulation commercialization platform [4][5]. Financial Performance Summary - For 2024, the company achieved a revenue of 39.24 billion yuan and a net profit of 8.26 billion yuan, with Q4 showing a revenue increase of 5.84% year-on-year [4][5]. - The report highlights a significant decline in revenue from the heparin raw material segment, down 51.61% year-on-year, while the formulation business grew by 18.30% [4][5]. - The company is expected to see net profits of 1.063 billion yuan in 2025, with growth rates of 29%, 33%, and 30% projected for the following years [5][6]. Market Opportunities - The global biosimilar market is anticipated to grow rapidly as key biological drug patents expire, presenting significant opportunities for the company [5]. - The company has made strategic acquisitions and partnerships, including the full asset acquisition of Coherus BioSciences' adalimumab biosimilar, which has already generated over 70 million yuan in sales since its launch [5][6]. - The upcoming approval of liraglutide in April 2025 is expected to convert prior investments into substantial revenue growth [4][5].

Group 1 - This week, 10 listed companies announced share buybacks and capital increase through special loans, including Weichai Power, which received a commitment letter for a buyback loan not exceeding 900 million yuan [1][2] - Weichai Power plans to repurchase shares amounting to 500 million to 1 billion yuan to cancel and reduce its registered capital [1][2] Group 2 - Jianyou Co. announced a buyback with loan support not exceeding 36 million yuan on May 22 [2] - Gongniu Group received a commitment letter for a buyback loan not exceeding 360 million yuan on May 22 [2] - Fenda Technology obtained a commitment letter for a buyback loan not exceeding 90 million yuan on May 21 [2] - Xingshuai Er received a commitment letter for a buyback loan not exceeding 34.55 million yuan on May 20 [2] - Hexing Packaging plans to repurchase shares between 50 million to 100 million yuan with a loan not exceeding 90 million yuan [2] - Anhui Construction's controlling shareholder received loan support not exceeding 180 million yuan for capital increase on May 23 [2] - Hubei Yihua's controlling shareholder obtained a commitment letter for a capital increase loan not exceeding 360 million yuan on May 22 [2] - Tunnel Co.'s controlling shareholder received loan support not exceeding 450 million yuan for capital increase on May 22 [2] - Shanghai Laishi's controlling shareholder plans to increase shares between 250 million to 500 million yuan with a loan not exceeding 450 million yuan [2]

Core Viewpoint - Nanjing Jianyou Biochemical Pharmaceutical Co., Ltd. has decided not to adjust the conversion price of its convertible bonds, despite triggering the downward adjustment clause due to stock prices falling below 90% of the current conversion price for 15 out of 30 trading days [2][7]. Group 1: Convertible Bond Details - The company issued 5,031,900 convertible bonds on April 23, 2020, with a total amount of 50.319 million yuan and a maturity of 6 years [3]. - The initial conversion price was set at 54.97 yuan per share, which has been adjusted to the latest price of 24.44 yuan per share [3][6]. - The conversion period for the bonds is from October 29, 2020, to April 22, 2026 [7]. Group 2: Price Adjustment History - The conversion price has undergone several adjustments due to various corporate actions, including stock incentive plans and profit distribution [4][5][6]. - Notable adjustments include a decrease from 54.97 yuan to 42.05 yuan due to the 2019 profit distribution and further adjustments down to 24.44 yuan as of July 8, 2024 [4][5][6]. Group 3: Decision on Price Adjustment - The board of directors held a meeting on May 23, 2025, and decided not to propose a downward adjustment of the conversion price, considering the long-term value of the company and the interests of all investors [2][7]. - The company will not propose any downward adjustment for the next six months, and any future decisions will be made after November 24, 2025, if the adjustment clause is triggered again [2][7].

一、可转债基本情况 经中国证券监督管理委员会"证监许可［2020］603号"文核准，南京健友生 化制药股份有限公司于2020年4月23日公开发行了5,031,900张可转换公司债券（以 下简称"可转债"），每张面值100元，发行总额50,319.00万元，期限为6年。 经上海证券交易所自律监管决定书［2020］134号文同意，公司50,319.00万元 可转换公司债券于2020年5月22日起在上海证券交易所挂牌交易，债券简称"健友 转债"，债券代码"113579"。 根据《上海证券交易所股票上市规则》等相关规定及《南京健友生化制药股份 有限公司公开发行可转换公司债券募集说明书》（以下简称"《募集说明书》"） 的约定，公司本次发行的"健友转债"自2020年10月29日起可转换为公司A股股票， 转股起止日期为2020年10月29日至2026年4月22日止。本次可转债的初始转股价格 为54.97元/股，最新转股价格为24.44元/股。 | 股票代码：603707 | 股票简称：健友股份 | 公告编号：2025-040 | | --- | --- | --- | | 债券代码：113579 | 债券简称：健友转债 | ...

Group 1 - Hongchuang Holdings plans to acquire 100% equity of Shandong Hongtuo Industrial for 63.518 billion yuan, transforming from a single aluminum deep processing business to a full industry chain including electrolytic aluminum, alumina, and aluminum deep processing [3] - LIZHU Group intends to acquire 64.81% of Vietnam's Imexpharm Corporation for approximately 1.587 billion yuan, enhancing its presence in the pharmaceutical sector [4][5] - China Power Construction reported a new contract amount of 386.49 billion yuan from January to April, a year-on-year decrease of 4.9% [7] Group 2 - Wanhua Chemical announced a scheduled maintenance for its production facilities, including a five-month technical upgrade for its Yantai ethylene unit, which will not significantly impact operations [8] - Changhong High-Tech received a warning letter from the Ningbo Securities Regulatory Bureau for failing to disclose related party transactions in a timely manner [9] - Highgreat plans to invest 10 million yuan in Blue Core Computing, which focuses on RISC-V architecture chips [10] Group 3 - Xidi Micro plans to increase capital by 30 million USD in its wholly-owned subsidiary Hong Kong Xidi Micro to support its expanding business [12] - Bichuang Technology lost its high-tech enterprise qualification, resulting in an increase in corporate income tax rate from 15% to 25% for the years 2023 to 2025 [13] - Tonghua Dongbao intends to transfer 5.7% of its shares in Xiamen Tebao Biological Engineering for a total of 1.301 billion yuan [16] Group 4 - Tian Tie Technology signed a strategic cooperation agreement with Shenzhen Xinjie Energy to collaborate on solid-state battery lithium metal anode materials [23] - Nanjing Port disclosed that its stock trading has shown signs of market sentiment overheating, indicating potential irrational trading behavior [24] - Zhongnan Media signed a government procurement contract worth 1.009 billion yuan, ensuring stable revenue for its main business [25]

关于获得A股股份回购资金贷款支持的公告 | 证券代码：603707 | 证券简称：健友股份 | 公告编号：2025-039 | | --- | --- | --- | | 债券代码：113579 | 债券简称：健友转债 | | 南京健友生化制药股份有限公司 股票回购贷款额度不代表公司对回购金额的承诺，具体回购 A 股股份的金额 以回购期限届满或回购 A 股股份方案实施完毕时实际回购的金额为准。 公司将严格按照《上市公司股份回购规则》《上海证券交易所上市公司自律 监管指引第 7 号——回购股份》等相关规定，在回购期限内根据市场情况择机做 出回购决策并予以实施，同时根据回购 A 股股份事项进展情况及时履行信息披露 义务，敬请广大投资者注意投资风险。 特此公告。 南京健友生化制药股份有限公司董事会 2025 年 5 月 23 日 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 南京健友生化制药股份有限公司（以下简称"健友股份"或"公司"）于 2025 年 4 月 28 日召开了第五届董事会第十二次会议，审议通过了《关于拟通过集 ...

Group 1 - The company will suspend the conversion of its convertible bonds, "Jianyou Convertible Bonds," from May 28, 2025, until the equity distribution registration date due to the implementation of the 2024 annual profit distribution [1][2][3] - The profit distribution plan approved by the shareholders' meeting includes a cash dividend of 1.00 yuan (including tax) for every 10 shares held, based on the total share capital registered on the equity distribution registration date [1][2] - The company will adjust the conversion price of the "Jianyou Convertible Bonds" in accordance with the terms outlined in the bond issuance prospectus following the equity distribution [2][3] Group 2 - The company will publish the relevant equity distribution implementation announcement and the convertible bond conversion price adjustment announcement on May 29, 2025 [2] - Holders of "Jianyou Convertible Bonds" must convert their bonds before May 27, 2025, to enjoy the equity distribution [3] - For detailed information regarding the "Jianyou Convertible Bonds," investors are directed to the bond issuance prospectus published on May 20, 2020 [3]

证券代码：603707 证券简称：健友股份 公告编号：2025-038 债券代码：113579 债券简称：健友转债 南京健友生化制药股份有限公司 关于实施权益分派时"健友转债" 转股连续停牌的提示性公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 权益分派实施公告前一交易日（2025 年 5 月 28 日）至权益分派股权登记日期 间，南京健友生化制药股份有限公司（以下简称"公司"）2020 年 4 月公开发 行的可转换公司债券（以下简称"健友转债"）将停止转股。 证券停复牌情况：适用 因实施 2024 年年度权益分派,本公司的相关证券停复牌情况如下： | 证券代码 | 证券简称 | 停复牌类型 | 停牌起始日 | 停牌 | 停牌终止日 | 复牌日 | | --- | --- | --- | --- | --- | --- | --- | | | | | | 期间 | | | | 113579 | 健友转债 | 可转债转股停 | 2025/5/28 | | | | | | | 牌 | | | | | 因实施权 ...

Group 1: Company Insights - The company, Jianyou Co., stated that the pharmaceutical industry is less affected by policies due to its essential nature and high regulatory barriers, despite facing a 20% tariff challenge [1] - Jianyou Co. has begun adjusting its raw material supply chain for affected products and is focusing on high-barrier, high-margin products to maintain its competitive edge [1] - The company plans to expand into markets in Europe, the Middle East, and Central and South America, aiming to become a global enterprise by 2030 [1] Group 2: Product Development and Market Performance - The company believes that the administrative order for product price reductions mainly impacts original research products, with limited effects on biosimilars or generics [1] - Progress on biosimilars is on track, with Liraglutide expected to receive FDA approval in April 2024, and sales of Adalimumab (Yusimry) exceeding 70 million yuan [1] - The pipeline includes collaborations with Tonghua Dongbao on insulin products and with Double Star Pharmaceutical on albumin-bound paclitaxel, both showing promising progress [1]